secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269529
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen receives $6.4M holdback payment from AstraZeneca on China sale
-----------------------------------------------------------------------

- Received $6.4M from AstraZeneca, satisfying $6.0M first holdback plus $0.4M net cash adjustment.
- China operations sale closed Aug 29, 2025; total consideration ~$220M ($85M enterprise + ~$135M net cash).
- $210M paid at closing; $4.0M second holdback for indemnity claims remains, releasable nine months post-close.
- Payment marks release of first post-closing holdback under February 2025 share purchase agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312525269529/0001193125-25-269529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312525269529/fgen-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer